drug
COLCHICINE
Marketedupdated 3mo agoby $SCLX Scilex Holding Co
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(2)
Trials studying COLCHICINE
- phase2A Study of SSGJ-613 in Gout Participants Initiating Urate-Lowering Treatment
- phase4Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias
- phase4MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
- phase2Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
- phase2Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain
- phase2A Study of the Efficacy of Genakumab in Prevention of Acute Flares in Gout Patients Initiating Urate-lowering TherapyUrate-lowering (GenSci048-202)
- phase3Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)
- phase2Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
Patent cliff
source: FDA Orange Bookfirst barrier falls
Oct 6, 2028
~2.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (41)
- Dec 20, 2037formulationUS 10226423
- Nov 22, 2036formulationUS 10383820
- Nov 22, 2036formulationUS 10383821
- Nov 22, 2036method-of-use (U-2814)US 12274751
- Nov 22, 2036method-of-use (U-2814)US 12514819
- Nov 22, 2036formulationUS 9907751
- May 9, 2034method-of-use (U-3642)US 10130585
- Nov 1, 2033method-of-use (U-3641)US 10206891
- Nov 1, 2033method-of-use (U-3639)US 10265281
- Nov 1, 2033method-of-use (U-3640)US 10842762
- Nov 1, 2033method-of-use (U-3639)US 11026899
- Nov 1, 2033method-of-use (U-3639)US 11026900
- Nov 1, 2033method-of-use (U-3638)US 11026901
- Nov 1, 2033method-of-use (U-3864)US 11944594
- Nov 1, 2033method-of-use (U-3868)US 11944595
- Nov 1, 2033method-of-use (U-4132)US 12233035
- Nov 1, 2033method-of-use (U-4168)US 12280025
- Nov 1, 2033method-of-use (U-3639)US 12364675
- Nov 1, 2033method-of-use (U-3643)US 9744144
- Aug 22, 2033method-of-use (U-1020)US 8927607
- Aug 22, 2033method-of-use (U-1020)US 9399036
- Aug 22, 2033method-of-use (U-1020)US 9555029
- Aug 22, 2033method-of-use (U-1020)US 9675613
- Aug 22, 2033method-of-use (U-1020)US 9789108
- Feb 17, 2029method-of-use (U-1020)US 78206812.5y
- Feb 17, 2029method-of-use (U-1116)US 79065192.5y
- Feb 17, 2029method-of-use (U-1007)US 79152692.5y
- Feb 17, 2029method-of-use (U-1007)US 84407212.5y
- Feb 17, 2029method-of-use (U-1020)US 84407222.5y
- Feb 10, 2029method-of-use (U-1007)US 76017582.5y
- Dec 3, 2028method-of-use (U-1020)US 76190042.3y
- Dec 3, 2028method-of-use (U-1116)US 79357312.3y
- Oct 6, 2028method-of-use (U-1007)US 79646472.1y
- Oct 6, 2028method-of-use (U-1161)US 79646482.1y
- Oct 6, 2028method-of-use (U-1166)US 79819382.1y
- Oct 6, 2028method-of-use (U-1007)US 80932962.1y
- Oct 6, 2028method-of-use (U-1161)US 80932972.1y
- Oct 6, 2028method-of-use (U-1116)US 80932982.1y
- Oct 6, 2028method-of-use (U-1020)US 80976552.1y
- Oct 6, 2028method-of-use (U-1007)US 84153952.1y
- Oct 6, 2028method-of-use (U-1007)US 84153962.1y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 16m ago
Found something off?
comments(0)
5-min edit window · permanent after that